Reaction of [RhClL 2 ] 2 (L = cyclooctene or ethylene) with 2 equiv of the phosphine {1-Et-2,6-(CH 2 P t Bu 2 ) 2 C 6 H 3 } ( 1 ) in toluene results in a selective metal insertion into the strong Ar−Et bond. This reaction proceeds with no intermediacy of activation of the weaker sp 3 −sp 3 ArCH 2 −CH 3 bond. The identity of complex Rh(Et){2,6-(CH 2 P t Bu 2 ) 2 C 6 H 3 }Cl ( 3 ) was confirmed by preparation of the iodide analogue 6 by reaction of the new Rh( η 1 -N 2 ){2,6-(CH 2 P t Bu 2 ) 2 C 6 H 3 } ( 7 ) with EtI. It is possible to direct the bond activation process toward the benzylic C−H bonds of the aryl−alkyl group by choice of the Rh(I) precursor, of the substituents on the phosphorus atoms ( t Bu vs Ph), and of the alkyl moiety (Me vs Et). A Rh(III) complex which is analogous to the product of insertion into the ArCH 2 −CH 3 bond (had it taken place) was prepared and shown not to be an intermediate in the Ar−CH 2 CH 3 bond activation process. Thus, aryl−C activation by Rh(I) is kinetically preferred over activation of the alkyl−C bond in this system. Moreover, cleavage of an Ar−CH 2 CH 3 bond, followed by β-H elimination, may be preferred over sp 2 −sp 3 C−C activation of an Ar−CH 3 group.
No takes yet. Share an insight, caveat, or question.
Boom et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: